Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 9, 2004, Pages 3185-3195

  Radosevich, Michael ^a   Song, Zhimin ^a   Gorga, Joan C ^a   Ksander, Bruce ^b   Ono, Santa Jeremy ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLASS II MAJOR HISTOCOMPATIBILITY ANTIGEN TRANSACTIVATOR; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GENE PRODUCT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; EPIGENETICS; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE INDUCTION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MELANOCYTE; MELANOMA CELL; PHENOTYPE; PRIORITY JOURNAL; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TROPHOBLAST; UVEA MELANOMA; WESTERN BLOTTING;

CELL NUCLEUS; CELLS, CULTURED; DNA-BINDING PROTEINS; EXTRACELLULAR SPACE; EYE NEOPLASMS; GENE SILENCING; GENES, MHC CLASS II; GENETIC VECTORS; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON TYPE II; MELANOCYTES; MELANOMA; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; UVEA;

EID: 4344701309     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0111     Document Type: Article

References (36)

1. Abdulkadir SA, Ono SJ. How are class II MHC genes turned on and off? FASEB J. 1995;9:1429-1435.
2. Radosevich M, Ono SJ. Novel mechanisms of class II major histocompatibility complex gene regulation. Immunol Res. 2003;27: 85-106.
3. Jager MJ, Hurks HM, Levitskaya J, Kiessling R. HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol. 2002;63:444-451.
4. Hu DN, Savage HE, Roberts JE. Uveal melanocytes, ocular pigment epithelium, and Muller cells in culture: in vitro toxicology. Int J Toxicol. 2002;21:465-472.
5. Chang CH, Fontes JD, Peterlin M, Flavell RA. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med. 1994;180:1367-1374.
6. Arlotta P, Miyazaki D, Copeland NG, Gilbert DJ, Jenkins NA, Ono SJ. Murine NFX. 1: isolation and characterization of its messenger RNA, mapping of its chromosomal location and assessment of its developmental expression. Immunology. 2002;106:173-181.
7. Tai AK, Zhou G, Chau K, Ono SJ. Cis-element dependence and occupancy of the human invariant chain promoter in CIITA-dependent and -independent transcription. Mol Immunol. 1999;36:447-460.
8. Casolaro V, Georas SN, Song Z, et al. Inhibition of NF-AT-dependent transcription by NF-kappa B: implications for differential gene expression in T helper cell subsets. Proc Natl Acad Sci USA. 1995;92:11623-11627.
9. Abdulkadir SA, Krishna S, Thanos D, Maniatis T, Strominger JL, Ono SJ. Functional roles of the transcription factor Oct-2A and the high mobility group protein I/Y in HLA-DRA gene expression. J Exp Med. 1995;182:487-500.
10. Harton JA, Ting JP. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol. 2000; 20:6185-6194.
11. Fedoseyeva EV, Boisgerault F, Anosova NG, et al. CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice. J Immunol. 2000;164:5641-5651.
12. Arancibia-Carcamo CV, Osawa H, Arnett HA, et al. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites. Eur J Immunol. 2004;34:471-480.
13. Czarniecki CW, Chiu HH, Wong GH, McCabe SM, Palladino MA. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol. 1988;140:4217-4223.
14. Zuber P, Kuppner MC, De Tribolet N. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol. 1988;18:1623-1626.
15. Reimold AM, Kara CJ, Rooney JW, Glimcher LH. Transforming growth factor beta 1 repression of the HLA-DR alpha gene is mediated by conserved proximal promoter elements. J Immunol. 1993;151:4173-4182.
16. Lee YJ, Han Y, Lu HT, et al. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J Immunol. 1997;158: 2065-2075.
17. Nandan D, Reiner NE. TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action. J Immunol. 1997;158:1095-101.
18. Latron F, Jotterand-Bellomo M, Maffei A, et al. Active suppression of major histocompatibility complex class II gene expression during differentiation from B cells to plasma cells. Proc Natl Acad Sci USA. 1988;85:2229-2233.
19. Chang CH, Fodor WL, Flavell RA. Reactivation of a major histocompatibility complex class II gene in mouse plasmacytoma cells and mouse T cells. J Exp Med. 1992;176:1465-1469.
20. Silacci P, Mottet A, Steimle V, Reith W, Mach B. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J Exp Med. 1994;180:1329-1336.
21. Wolffe AP. Transcriptional control. Sinful repression. Nature. 1997;387:16-17.
22. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389:349-352.
23. Faulk WP, Sanderson AR, Temple A. Distribution of MHC antigens in human placental chorionic villi. Transplant Proc. 1977;9:1379-1384.
24. Sunderland CA, Naiem M, Mason DY, Redman CW, Stirrat GM. The expression of major histocompatibility antigens by human chorionic villi. J Reprod Immunol. 1981;3:323-331.
25. Billington WD, Bell SC. Immunoregulatory factors in pregnancy: essential or irrelevant in the maintenance of the fetoplacental allograft? Placenta Suppl. 1982;4:13-23.
26. Peyman JA, Hammond GL. Localization of IFN-gamma receptor in first trimester placenta to trophoblasts but lack of stimulation of HLA-DRA, -DRB, or invariant chain mRNA expression by IFN-gamma. J Immunol. 1992;149:2675-1680.
27. Murphy SP, Tomasi TB. Absence of MHC class II antigen expression in trophoblast cells results from a lack of class II transactivator (CIITA) gene expression. Mol Reprod Dev. 1998;51:1-12.
28. Morris AC, Spangler WE, Boss JM. Methylation of class II transactivator promoter IV: a novel mechanism of MHC class II gene control. J Immunol. 2000;164:4143-4149.
29. Hunt JS, Orr HT. HLA and maternal-fetal recognition. FASEB J. 1992;6:2344-2348.
30. Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol. 1993;151:4562-4573.
31. Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today. 1997;18:478-42.
32. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Nall Acad Sci USA. 1997;94:11520-11525.
33. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191-1193.
34. van den Elsen PJ, van der Stoep N, Vietor HE, Wilson L, van Zutphen M, Gobin SJ. Lack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFN-gamma inducible promoter (PIV) of CIITA. Hum Immunol. 2000;61:850-862.
35. van den Elsen PJ, Gobin SJ, van der Stoep N, Datema G, Vietor HE. Transcriptional control of MHC genes in fetal trophoblast cells. J Reprod Immunol. 2001;52:129-145.
36. van Der Stoep N, Biesta P, Quinten E, van Den Elsen PJ. Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int J Cancer. 2002;97:501-507.